NCT06616077View on ClinicalTrials.gov

Endometrial Transcript Profile with Progesterone After Post-ovulatory Mifepristone

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 7, 2022

Primary Completion Date

April 27, 2023

Study Completion Date

May 8, 2023

Conditions
Endometrial Endocrine RegulationProgesterone Supplementation in Women After Mifepristone
Interventions
DRUG

Micronized Progesterone 600 mg

Vaginal supplementary micronized progesterone will be given after postovulatory administration of the progesterone receptor antagonist mifepristone. Administration from LH+3 to LH+5 (LH peak=LH+0); 200 mg 3 times per day.

DRUG

mifepristone 200 mg

Post ovulatory single oral administration (LH+2, LH peak=LH+0)

DRUG

Oral Placebo Tablet

Oral placebo tablet containing brewer yeast, cellulose, stearic acid, silica, magnesium stearate

DRUG

Placebo Vaginal

Cocoa butter

Trial Locations (1)

8360160

Hospital San Borja Arriarán, Santiago

All Listed Sponsors
lead

Reproductive Health Research Insritute, Chile

OTHER